New England Journal of Medicine Archives
Study shows two vaccine doses for mothers eases COVID complications for infants
Jul. 6, 2022—Infants younger than 6 months were better protected from COVID-19 complications when mothers received two doses of the vaccine while pregnant, according to Vanderbilt researchers.
Research probes cause of acute flaccid myelitis in children
Jun. 8, 2022—Research that began at Vanderbilt University Medical Center has found evidence that a viral infection followed by a “robust” immune response is the cause of a polio-like paralyzing illness in children called acute flaccid myelitis (AFM).
VUMC-led study finds Moderna COVID vaccine safe and effective for children
May. 12, 2022— by Bill Snyder Moderna’s COVID-19 vaccine is safe and generates robust immune responses in children ages 6 to 11 years, a national clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found. The two-dose vaccine (given approximately one month apart) led to antibody responses in more than...
New study illustrates how much it would cost for cancer drugs covered under Medicare Part D
May. 10, 2022—A new study by Vanderbilt researchers highlights how some older Americans diagnosed with cancer can face unlimited out-of-pocket spending for prescription drugs under the current structure of the Medicare Part D benefit.
Study finds azithromycin use during RSV not useful in preventing recurrent wheezing, may cause harm
Feb. 28, 2022—Vanderbilt research on the impact of the antibiotic azithromycin during severe respiratory syncytial virus (RSV) bronchiolitis overwhelmingly support current national bronchiolitis guidelines, which recommend against antibiotics during acute bronchiolitis due to lack of effect on the acute illness.
International study supports dupilumab for treatment of moderate-to-severe asthma in children
Dec. 8, 2021—In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11 with moderate-to-severe asthma, offering a new option to these patients.
VUMC is pacesetter for national aspirin study
May. 20, 2021—According to an innovative large-scale clinical trial reported last week in the New England Journal of Medicine, a single daily baby aspirin (81 mg) or a single daily adult aspirin (325 mg) are equally safe and effective for prevention of adverse cardiovascular events for patients with established atherosclerotic cardiovascular disease.
Study finds recommended ICU sedatives equally safe, effective
Feb. 2, 2021—Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.
Treating appendicitis with antibiotics instead of surgery may be good option for some, but not all, patients
Oct. 5, 2020—Antibiotics instead of surgery may be a good choice for some, but not all, patients with appendicitis, according to results from a study reported today in the New England Journal of Medicine.
New data offer insights on COVID treatments for people with cancer
Jul. 22, 2020—Newly released data on treatment outcomes of people with cancer diagnosed with COVID-19 reveal a racial disparity in access to Remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite effect in the general patient population.
VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial
Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
Article examines need for genotyping after stenting
Oct. 24, 2019—Genotyping can improve outcomes in patients who require anti-platelet therapy following stent placement to open narrowed or blocked coronary arteries and prevent a heart attack.
